东诚药业：177Lu-LNC1009注射液临床试验获批 目前国内外暂无同产品上市

Core Viewpoint - Dongcheng Pharmaceutical (002675.SZ) announced that its subsidiary Yantai Lannacheng Biotechnology Co., Ltd. received approval from the National Medical Products Administration of China for clinical trials of the drug 177Lu-LNC1009, which will commence shortly [1] Group 1 - The product 177Lu-LNC1009 is a dual-target radioactive internal therapy drug that targets fibroblast activation protein (FAP) and integrin αvβ3, intended for the treatment of patients with advanced malignant solid tumors that are positive for FAP and integrin αvβ3 [1] - There are currently no similar products available in the domestic or international markets, nor are there any related sales data [1]